$13.26 0.41 (+3.19%)
2/13/2012 4:02 PM

Elan Corp, plc (ADR) (NYSE:ELN)

CAPS Rating: 4 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

1
Player Avatar adambutz (< 20) Submitted: 6/1/2009 9:22:14 AM : Outperform Start Price: $8.00 ELN Score: +19.73

Takeover target by Bristol Myers!

Report this Post Add Comment

Featured Broker Partners


Advertisement